AlzeCure Confident Of Bagging Partner For Pain Drug
Phase II For Non-Opioid Fully Enrolled
Executive Summary
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.